A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)
CLN-978-SL-101
Phase 1 other active
Quick answer
A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE) for Systemic Lupus Erythematosus is a Phase 1 program (other) at Cullinan Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cullinan Therapeutics
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 1
- Modality
- other
- Status
- active